

# Exploring Herbal Remedies for Peptic Ulcer: A Natural Approach to Gastric Healing

Virendra Kumar Singh<sup>1\*</sup>, Binish Ameen<sup>1</sup>

<sup>1</sup>Faculty of Pharmaceutical Sciences Rama University Kanpur, Uttar Pradesh  
209217, India,

\*Corresponding Author Name - Virendra Kumar Singh

Affiliation – Research Scholar Faculty of Pharmaceutical Sciences Rama University Kanpur, Uttar Pradesh  
209217, India,

mail id: [psvirendra012@gmail.com](mailto:psvirendra012@gmail.com)

## Abstract


The term "peptic ulcer" (PU) refers to a group of chronic symptoms that affect the mucosal integrity of the stomach and/or duodenal lining and are characterised by pain, perforations, bloating, nausea, blood in the stool or vomit, loss of appetite, and weight loss. The goal of this review is to summarize the various phytoconstituents that have been investigated for their anti-ulcer potential in various preclinical studies. Herbal drugs are alternative remedies for the treatment of various pharmacological conditions and are generally thought to be much safer than synthetic drugs. Recently there has been a growing interest in herbal remedies for their potential efficacy, availability, and safety profile. This review explores the Pathophysiology of peptic ulcers, commonly used herbal treatments, and their mechanisms of action.

**Keywords:-** Peptic ulcer, Phytomedicine, Herbal drugs, Synthetic drugs, Preclinical studies.

## Introduction

A prevalent source of gastrointestinal morbidity and mortality, peptic ulcers (PU) are a collective term for a variety of chronic symptoms that impair the stomach's mucosal integrity and/or the duodenal lining. [1] It is a digestive tract lesion caused by acid that is characterized by denuded mucosa that extends into the muscularis propria or submucosa. [2, 3] Epigastric discomfort, perforations, bloating, nausea, blood in the stool or vomit, appetite reduction, and weight loss are its hallmarks. [4-7] According to estimates, there are 200–250 cases of PU for every 100,000 people worldwide, with developing nations having higher rates. [8] Although PU can begin at any age and affects both sexes equally, the condition often manifests between the ages of 10-15. [9-12]. A key mechanism in the Pathophysiology of the disease is said to be an imbalance between aggressive (free radicals, excess secretion of gastric acid, and pepsin) and defensive (decreased bicarbonate production, prostaglandins (PGs), nitric oxide (NO), and anti-oxidants) factors in the gastric mucosa. [13]. Helicobacter pylori infection (H-Pylori), alcohol usage, Zollin-Ellison syndrome, and non-steroidal anti-inflammatory drug use are risk factors for peptic ulcer development. [14]

The World Health Organisation (WHO) estimates that over 80% of people worldwide treat their medical issues with traditional medicine. Since ancient times, herbal products have been used as lead compounds to identify a variety of bioactive chemicals. They are regarded as being far safer than synthetic compounds and are frequently utilized in traditional medical systems to cure a variety of illnesses as well as provide additional health benefits. [15-17]



**Figure.01. Peptic Ulcer** [18]

Herbal medications are being investigated as a viable substitute for synthetic compounds due to the exponential rise in the prevalence of chronic diseases like cancer, diabetes, cardiovascular disorders, ulcerative colitis, and acquired immune deficiency syndrome that necessitate long-term, often lifetime, medication. [19]

Additionally, a number of preclinical and clinical studies have documented the safety and effectiveness of plant-derived products in a variety of pathological disorders in recent decades. [20]

In the United States, antacids and anticholinergics were the primary treatments for peptic ulcers until the late 1970s. Surgery was often required to address the condition [21]. In 1976, histamine-2-receptor antagonists (H2RAs) were first made available. *Helicobacter pylori*, formerly known as *Campylobacter pyloridis*, were first identified in stomach biopsies by Dr. J. Robin Warren. [22]

Dr. Barry Marshall cultured *H. pylori* from ulcer and gastritis patients in 1982. Nevertheless, [23-26]. 1994 National Institutes of Health guidelines did not advocate the use of antibiotics in the therapy for patients with *H. pylori*-related peptic ulcer disease. There had been a decline in the incidence of peptic ulcer illness by the end of the 20th century. Raising hygiene standards is thought to be the cause of the population's declining *H. pylori* infection rate [27-28] we emphasise recent developments in treatment approaches and provide an update on the diagnosis of peptic ulcer disease [29].

In 1997, the Centers for Disease Control and Prevention, in collaboration with various government entities, academic institutions, and industry stakeholders, initiated a nationwide educational campaign aimed at raising awareness among healthcare providers and consumers regarding the connection between *H. pylori* and ulcers

[30]. This initiative emphasized that ulcers are a treatable infection and highlighted the potential for significant health improvements and cost savings through the distribution of information about *H. pylori*. Later that same year, [31] in a randomized control trial conducted in 2001, Chan *et.al.* Demonstrated that the eradication of *H. pylori* can prevent bleeding from ulcers induced by aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) [32].

### Conventional treatment approaches

Current antiulcer medications aim to achieve remission as soon as feasible and sustain it for a lengthy period of time, in addition to limiting the disease's progression. [33–35] Histamine-2 receptor antagonists (cimetidine, ranitidine, famotidine, nizatidine); proton pump inhibitors (omeprazole, lansoprazole, pantoprazole, rabeprazole); prostaglandin analogues (misoprostol); antacids (sodium bicarbonate, aluminium hydroxide, magnesium trisilicate); protectants (sucralfate, bismuth); and antimicrobial agents (metronidazole, tetracycline, amoxi cillin, Clarithromycin) are employed in the treatment of PU. [36–41] Iron supplements have also been used to treat PU; they are used in conjunction with aluminium hydroxide to prevent stomach discomfort. [42–44]

### Types of peptic ulcer

Peptic ulcers can be divided into categories according to their location.

Gastric ulcer: - It occurrence of the ulcer in stomach.

Duodenal ulcer: - It occurrence of the ulcer in duodenal and intestine

Esophagus ulcer: - It occurrence of the ulcer in esophagus

Aphthous Ulcer:- It is also known as mouth ulcer it occurrence of the ulcer in mouth [45]. Ulcers are many types like Corneal ulcer, Genital ulcer, Liver ulcer and etc. Individuals with this condition demonstrate increased levels of acid secretion. Peptic ulcers are classified according to their severity into two main types: [46].

**Acute Peptic Ulcer:** These ulcers penetrate to the sub mucosal layer and can manifest as either single or multiple lesions. They are often found in various regions of the stomach and the first few centimeters of the duodenum [47].

**Chronic Peptic Ulcer:** These ulcers extend through the epithelial and muscular layers of the stomach wall and may affect adjacent organs like the pancreas or liver. In most instances, they appear as solitary ulcers in the pyloric antrum of the stomach and the duodenum [48].

## Symptoms of peptic ulcer

Abdominal discomfort is the most common indication of a peptic ulcer, often fluctuating over several days each week. This discomfort typically arises 2 to 3 hours after eating and can also occur at night when the stomach is empty. Other associated symptoms may include blood loss leading to anemia, weight loss, poor appetite, bloating, burping, nausea, and vomiting. In advanced stages, patients may present with severe symptoms, including sharp, sudden, and persistent pain, as well as bloody or black stools and blood in vomit [49].

## Complication

Complications associated with peptic ulcer disease can arise from various underlying causes. These complications are significant contributors to the elevated morbidity and mortality rates linked to this condition [50]. The implementation of various gastro protection measures and eradication treatments for *Helicobacter pylori* infection has notably decreased the incidence of these complications compared to previous decades. Individuals who smoke regularly and those who use chronic NSAIDs are at a higher risk. The four primary complications of peptic ulcer disease include bleeding, perforation, penetration, and obstruction [51].

## Bleeding

The occurrence of bleeding has seen a slight reduction in recent years; however, it continues to be the most common complication, affecting around 10-20% of patients. This condition frequently leads to emergency room admissions. Ulcers linked to NSAID usage are more likely to result in bleeding than those caused solely by chronic *H. pylori* infection [52]. The elderly and individuals with serious health issues, such as respiratory, cardiac, cerebrovascular, and renal conditions, are at the highest risk [53]. It is important to note that 80-90% of upper gastrointestinal hemorrhages are not of variceal origin, with approximately 40-50% resulting from peptic ulcer disease. The mean mortality rate associated with this condition is about 5.5%. Clinical manifestations can vary widely: 15% of patients may experience melena, 30% may have hematemesis, 50% may present with both, and around 5% may show hematochezia due to severe bleeding. In some cases, ulcer bleeding may present as a chronic issue, leading to iron deficiency anemia or a positive fecal occult blood test [54].

## Perforation

Perforation occurs in approximately 5% of individuals with peptic ulcers, predominantly affecting 60% of duodenal ulcers, which are typically found on the anterior wall of the duodenal bulb. In contrast, 40% of gastric ulcers often involve the lesser curvature. A free perforation of either a duodenal or gastric ulcer into the peritoneal cavity poses a significant risk to the patient's life [55]. This condition is characterized by sudden, intense abdominal pain in the epigastric region, which may radiate to the back or become diffuse, often accompanied by acute shock, indicating a complicated ulcer perforation with peritonitis. Patients typically adopt a motionless posture with their thighs flexed towards the abdomen, creating an impression of gravity. Upon

examination, a hard, rigid abdomen with rebound tenderness is observed. Initial auscultation may reveal heightened intestinal sounds, which tend to diminish and eventually fade as the condition worsens. Approximately 70% of cases exhibit visible pneumoperitoneum on plain abdominal radiographs [56]. The causes of perforated duodenal ulcers are multifactorial, including alcohol, tobacco, *Helicobacter pylori*, and notably, the use of NSAIDs, which account for over a third of perforations, with figures reaching up to 50% in the elderly, often involving low-dose acetylsalicylic acid. Chronic cocaine use, although less common, is another potential cause, with its Pathophysiology remaining speculative, possibly linked to localized vasoconstriction or vascular thrombosis. [57]

## **Obstruction**

Obstruction is a relatively rare complication, constituting about 5% of ulcer-related issues. Up until around 1970, peptic ulcers were the most common reason for gastric emptying obstruction. In recent years, however, the occurrence of obstruction due to peptic ulcers has decreased, with gastric malignancies now being the leading cause of gastric outlet obstruction [58]. Obstructions caused by ulcers are typically found in the pyloric channel or duodenal bulb, arising from the swelling and edema associated with active ulceration or the healing process, which can lead to the tissue contraction [59].

## **Etiology & Pathology**

The most common causes of PUD (Peptic Ulcer Disease) are *H. pylori* infection and the use of nonsteroidal anti-inflammatory drugs (NSAIDs), but not everyone who has either of these factors will get the illness. About half of the world's population has the *H. pylori* bacteria in their stomachs, and most people get infected during childhood, and the infection does not go away unless it is treated. Overcrowding and dirty conditions, along with a lower socioeconomic status, are risk factors for illness. During the past five years, the prevalence of *H. pylori* has generally decreased. the United States among individuals of all ages. The infection rate varies significantly among ethnic groups; among Mexican Americans, the infection rate is 60%, while among non-Hispanic whites, it is 30% lower. The degeneration and destruction of epithelial cells is caused by the inflammatory response triggered by *H. pylori* in the stomach's mucosal layer; while it is normal for the antrum to be more inflamed than the corpus, this is not always the case; occasionally the inflammation is more concentrated in the corpus. It is crucial to screen those who have peptic ulcers to ensure they do not carry the *H. pylori* bacteria. [60]

## **Herbal products for treatment of PU**

Since ancient times, Phytochemical have been utilised to cure a variety of illnesses, and they are generally regarded as safer than synthetic medications. [61-63] they are widely available in nature and apart from therapeutic purposes, they are also consumed in the form of nutritional supplement [64]

Numerous preclinical studies have reported that several chemical constituents derived from plants have anti-ulcer properties. The class of alkaloids, tannins, flavonoids, terpenoids, glycosides, carotenoids, and saponins includes these elements.[65]

In the present manuscript, some of the important medicinal plants and their bioactive principles used for treatment of PU have been discussed. Plant taxonomy as per “The Plant List” has been used to write the names of the plants in this manuscript. [66]

### **Herbal Treatments for Peptic Ulcers**

#### **Cabbage (*Brassica oleracea*)**

Cabbage is rich in glutamine and vitamin U (S-methylmethionine), which promote mucosal repair and reduce gastric acid secretion. Studies suggest daily consumption of cabbage juice accelerates ulcer healing. [67]

#### **Licorice (*Glycyrrhiza glabra*)**

Licorice root enhances mucus secretion and inhibits the growth of *H. pylori*. Deglycyrrhizinated licorice (DGL) is particularly effective in reducing ulcer symptoms without raising blood pressure. [68]

#### **Aloe Vera (*Aloe barbadensis miller*)**

Aloe vera gel has anti-inflammatory and antioxidant properties, which help in reducing gastric acidity and promoting tissue repair. [69]

#### **Turmeric (*Curcuma longa*)**

Curcumin, the active compound in turmeric, exhibits anti-inflammatory and antibacterial properties. It reduces oxidative stress and inhibits *H. pylori* growth. [70]

#### **Bananas (*Musa spp.*)**

Bananas contain sitoindosides, which increase mucus secretion and provide a protective barrier against gastric acid. [71]

#### **Neem (*Azadirachta indica*)**

Neem leaves have been shown to reduce gastric acid secretion and promote healing by increasing the production of gastric mucus. [72]

#### **Fenugreek (*Trigonella foenum-graecum*)**

Fenugreek seeds are rich in mucilage, which forms a protective coat on the stomach lining, preventing damage from acid and pepsin. [73]

## Plant extracts and phytoconstituents in peptic ulcer

Various medicinal plants are used traditionally in the treatment of peptic ulcer. Plants and Phytomedicine exhibit their action by various mechanisms like antioxidant, cytoprotective, antisecretory action. Some of the plants and their phytoconstituents showing antiulcerogenic activity are tabulated in Table 1

**Table 1: Some Medicinal plants having antiulcerogenic activity**

Sr. no	Botananical name / family	Traditional uses	Plant part used	Chemical constituent
01.	<i>Jasminum grandiflorum</i> Family: Oleaceae	skin diseases, ulcers, wounds, otalgia, leprosy, otorrhoea, dysmenorrhoea	leaves	alkaloids, saponins, phenolics, flavonoids, carotenoids, glycosides and carbohydrates.[74]
02.	<i>Solanum nigrum</i> Family: Solanaceae	liver disorders, skin disease, fevers, inflammatory conditions, painful periods, diarrhoea, eye diseases, ulcer	Fruits	tannins, alkaloids, carbohydrates, saponins, volatile oil and anthocyanins. [75,76]
03.	<i>Ocimum sanctum</i> Family: Labiatae	asthma, chronic fever, cold, cough, malaria, dysentery, convulsions, diabetes, diarrhea, arthritis, emetic syndrome etc.	Leaves	eugenol, carvacrol, caryophyllene, apigenin, luteolin, apigenin-7-O-glucuronide, orientin, molludistin and ursolic acid.[77,78]
04.	<i>Asparagus racemosus</i> Family: Liliaceae	antispasmodic, astringent, antidiarrhoeatic, antidysentric, useful in tumours, throat infection, leprosy etc.	Root	Total saponins like shatavarin I–IV. [79]
05.	<i>Amomum subulatum</i> Family: Zingiberaceae	In gastrointestinal disorders, digestive, stomachic, antiemetic and carminative	Fruit	essential oils, anthocyanins, aurone and flavanone.[80]



## Mechanism of Action of Herbal Remedies

Herbal treatments for peptic ulcers work through various mechanisms:

**Antibacterial Action:** Inhibition of *H. pylori*.

**Anti-inflammatory Properties:** Reduction of inflammation and oxidative stress.

**Mucosal Protection:** Enhancement of mucus and bicarbonate secretion.

**Acid Neutralization:** Reduction of gastric acid secretion.

## Challenges and Limitations

While herbal remedies show potential, challenges such as variability in plant composition, lack of standardization, and insufficient clinical trials remain significant barriers. Further research is needed to validate their efficacy and safety in long-term use.

## Conclusion

Herbal remedies provide a natural and holistic approach to managing peptic ulcers. With increasing evidence of their efficacy, these treatments hold promise as an adjunct or alternative to conventional therapies. However, their use should be guided by scientific evidence and medical supervision.

## Acknowledgments

I would like to express my sincere gratitude to Dr. Neelam Jain for their invaluable assistance in reviewing and providing constructive feedback on this article. I also appreciate the support of Rama University faculty of pharmaceutical sciences Kanpur for providing the necessary resources to carry out this review.

## Ethical consent

This review article does not involve original research involving human participants or animals. Therefore, ethical approval and informed consent were not required.

## Conflicts of interest

There are no conflicts of interest.

## Future direction

Future prospects in herbal treatment for peptic ulcers include advanced phytochemical research, clinical validation, herbal-drug synergy, innovative delivery systems, personalized herbal medicine, and standardized formulations for regulatory approval.



## References

1. Proctor, M.J., Deans, C., 2014. Complications of peptic ulcers. *Surgery* 32, 599–607.
2. Ippoliti, A., Walsh, J., 1976. Newer concepts in the pathogenesis of peptic ulcer disease. *Surg. Clin. North Am.* 56, 1479–1490.
3. Kuna, L., Jakab, J., Smolic, R., Raguz-Lucic, N., Vcev, A., Smolic, M., 2019. Peptic ulcer disease: a brief review of conventional therapy and herbal treatment options. *J. Clin. Med.* 8. <https://doi.org/10.3390/jcm8020179>
4. Katz, J., 1991. The course of peptic ulcer disease. *Med. Clin. North Am.* 75, 831–840,
5. Malfertheiner, P., Chan, F.K.L., McColl, K.E.L., 2009. Peptic ulcer disease. *Lancet North Am. Ed.* 374, 1449–1461.
6. Prabhu, V., Shivani, A., 2014. An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults. *Ann. Med. Health Sci. Res.* 4, 22–29
7. Meijs, S., Gardenbroek, T.J., Sprangers, M.A.G., Bemelman, W.A., Buskens, C.J., D'Haens, G.R.A.M., Lowenberg, M., 2014. Health-related quality of life and disability in patients with ulcerative colitis and proctocolectomy with ileoanal pouch versus treatment with anti-TNF agents. *J. Crohn's and Colitis* 8, 686–692.
8. Asali, A.M., Alghamdi, M.A., Fallatah, S.A., Alholaily, W.A., Aldandan, R.G., Alnosair, A.H., AlKhars, A.A., Alreheli, M.F., Almohaini, M.O., Alharbi, R.A., 2018. Risk factors leading to peptic ulcer disease: systematic review in literature. *Int. J. Commun. Med. Public Health* 5, 4617–4624.
9. Lanas, A., García-Rodríguez, L.A., Polo-Tomas, M., Ponce, M., Quintero, E., Perez-Aisa, M.A., Gisbert, J.P., Bujanda, L., Castro, M., Munoz, M., Del-Pino, M.D., ~ Garcia, S., Calvet, X., 2011. The changing face of hospitalisation due to gastrointestinal bleeding and perforation. *Aliment. Pharmacol. Ther.* 33, 585–591
10. Sonnenberg, A., 1987. Causative factors in the etiology of peptic ulcer disease become effective before the age of 15 years. *J. Chronic. Dis.* 40, 193–202.
11. Sonnenberg, A., 2013. Review article: historic changes of *Helicobacter pylori*-associated diseases. *Aliment. Pharmacol. Ther.* 38, 329–342.
12. Susser, M., 1967. Causes of peptic ulcer: a selective epidemiologic review. *J. Chronic. Dis.* 20, 435–456.
13. Avinash, K., Abha, D., Ganesh, N.S., 2011. Peptic ulcer: a review with emphasis on plants from Cucurbitaceae family with antiulcer potential. *Int. J. Res. Ayurveda & Pharm.* 2, 1714–1716
14. Menguy, R., 1970. Pathophysiology of peptic ulcer. *Am. J. Surg.* 120, 282–293
15. Salehi, B., Ata, A., Kumar, N.V.A., Sharopov, F., Ramírez-Alarcon, K., Ruiz-Ortega, A., Ayatollahi, S.A., Fokou, P.V.T., Kobarfard, F., Zakaria, Z.A., Iriti, M., Taheri, Y., Martorell, M., Sureda, A., Setzer, W.N, Durazzo, A., Lucarini, M., Santini, A., Capasso, R., Ostrander, E.A., Rahman, A-u., Choudhary,

- M.I., Cho, W.C., Sharifi-Rd, J., 2019. Antidiabetic potential of medicinal plants and their active components. *Biomolecules*.
16. Salehi, B., Zakaria, Z.A., Gyawali, R., Ibrahim, S.A., Rajkovic, J., Shinwari, Z.K., Khan, T., Sharifi-Rad, J., Ozleyen, A., Turkdonmez, E., Valussi, M., Tumer, T.B., Fidalgo, L.M., Martorell, M., Setzer, W.N., 2019. Piper species: a comprehensive review on their phytochemistry, biological activities and applications. *Molecules* 24. <https://doi.org/10.3390/molecules24071364>.
  17. Sharifi-Rad, J., Sharifi-Rad, M., Salehi, B., Iriti, M., Roointan, A., Mnayer, D., Soltani-Nejad, A., Afshari, A., 2018. In vitro and in vivo assessment of free radical scavenging and antioxidant activities of *Veronica persica* Poir. *Cell. Mol. Biol.* 64, 57–64.
  18. Sharifi-Rad, J., Melgar-Lalanne, G., Hernandez-Alvarez, A.J., Taheri, Y., Shaheen, S., Kregiel, D., Antolak, H., Pawlikowska, E., Brdar-Jokanovic, M., Rajkovic, J., Hosseinabadi, T., Ljevnaić-Masic, B., Baghalpour, N., Mohajeri, M., Fokou, P.V.T., Martins, N., 2020. Malva species: Insights on its chemical composition towards pharmacological applications. *Phytother. Res.* 34, 546–567.
  19. Sharifi-Rad, J., Rodrigues, C.F., Sharopov, F., Docea, A.O., Karaca, A.C., Sharifi-Rad, M., Karıncaoglu, D.K., Gulseren, G., Senol, E., Demircan, E., Taheri, Y., Suleria, H.A.R., Ozelik, B., Kasapoğlu, K.N., Gultekin-Ozguven, M., Daskaya-Dikmen, C., Cho, W.C., Martins, N., Calina, D., 2020. Diet, lifestyle and cardiovascular diseases: linking pathophysiology to cardioprotective effects of natural bioactive compounds. *Int. J. Environ. Res. Public Health*
  20. Choi, W., Choi, C.-H., Kim, Y.R., Kim, S.-J., Na, C.-S., Lee, H., 2016. HerDing: herb recommendation system to treat diseases using genes and chemicals. Database 2016.
  21. Marshall BJ. Unidentified Curved Bacillus On Gastric Epithelium In Active Chronic Gastritis. *Lancet* 1983 ;(8336):1273-75.
  22. Marshall BJ, Warren JR. Unidentified Curved Bacilli In The Stomach Patients With Gastritis And Peptic Ulceration. *Lancet* 1984;(8390):1311-15
  23. Kathryn Schulz. Stress Does Not Cause Ulcers! How To Win A Nobel Prize In One Easy Lesson: Barry Marshall On Being Right 2010. ([Http: //Www. Slate. Com/ Content /Slate /Blogs/The wrong stuff/2010/09](http://www.slate.com/content/slate/blogs/the_wrong_stuff/2010/09)).
  24. Van Der Weyden MB, Armstrong RM, Gregory AT. The 2005 Nobel Prize In Physiology Or Medicine. *Med J Aust*.2005;183(11- 12):612-4.
  25. Nobel Prize in Physiology or Medicine 2005 ([Http: //Www .Nobelprize. Org/ Nobel\\_ Prizes/Medicine/Laureates/2005/](http://www.nobelprize.org/Nobel_Prizes/Medicine/Laureates/2005/)).
  26. Ulcer Diagnosis And Treatment-CDC Bacterial, Mycotic Diseases ([Http: Www. Cdc.Gov/Ulcer/History,Htm](http://www.Cdc.Gov/Ulcer/History,Htm)).2014.
  27. Taylor DN, Blaser MJ. The Epidemiology of *Helicobacter Pylori* Infections. *Epidemiol.Rev.* 1991; 13:42-59)

28. Falush D, Wirth T, Linz B, et.al. Traces of Human Migration In *Helicobacter Pylori* Populations. *Science*.2003; 299:1582-58.
29. Chen Y, Blaser MJ. *Helicobacter Pylori* Colonization Is Inversely Associated With Childhood Asthma's *Infect Dis*.2008;198:553-60.
30. <http://www.cdc.gov/ulcer/history.htm>.
31. Tomb J, White O, Kerlavage A, Clayton RA, Sutton GG, Fleischmann RD, et al. The complete genome sequence of the gastric pathogen *Helicobacter pylori*. *Nature* 1997;388(6642):539–47.
32. Chan FKL, Chung S, Suen B, Lee Y, Leung W, Leung VKS, et al. Preventing recurrent upper gastrointestinal bleeding in patients with *Helicobacter pylori* infection who are taking low-dose aspirin or naproxen. *N Engl J Med* 2001; 344(13): 967–73.
33. Annahazi, A., Molnar, T., 2014. Pathogenesis of ulcerative colitis and Crohn's disease: similarities, differences and a lot of things we do not know yet. *J. Clin. Cellular Immunol*.
34. Hanauer, S.B., 2008. Review article: evolving concepts in treatment and disease modification in ulcerative colitis. *Aliment. Pharmacol. Ther.* 27, 15–21.
35. Probert, C.S.J., Dignass, A.U., Lindgren, S., Pool, M.O., Marteau, P., 2014. Combined oral and rectal mesalazine for the treatment of mild-to-moderately active ulcerative colitis: rapid symptom resolution and improvements in quality of life. *J. Crohn's and Colitis* 8, 200–207.
36. Cargill, J.M., Saunders, J.H., Peden, N., Wormsley, K.G., 1978. Very long-term treatment of peptic ulcer with cimetidine. *Lancet* 2, 1113–1115.
37. Huang, S.-C., Sheu, B.-S., Lee, S.-C., Yang, H.-B., Yang, Y.-J., 2010. Etiology and treatment of childhood peptic ulcer disease in Taiwan: a single center 9-year experience. *J. Formos. Med. Assoc.* 109, 75–81.
38. Johnson, H.D., Camb, M.B., 1957. The classification and principles of treatment of gastric ulcers. *Lancet North Am. Ed.* 270, 518–520.
39. Konturek, S.J., 1985. Prostaglandins in pathophysiology of peptic ulcer disease. *Dig. Dis. Sci.* 30, 108S
40. Malfertheiner, P., Chan, F.K.L., McColl, K.E.L., 2009. Peptic ulcer disease. *Lancet North Am. Ed.* 374, 1449–1461
41. Miehlke, S., Madisch, A., Kupcinkas, L., Petrauskas, D., Bohm, G., Marks, H.-J., Neumeyer, M., Nathan, T., Fernandez-Ba nares, F., Greinwald, R., Mohrbacher, R., ~ Vieth, M., Bonderup, O.K., 2014. Budesonide is more effective than mesalamine or placebo in short-term treatment of collagenous colitis. *Gastroenterology* 146, 1222–1230.
42. Prabhu, V., Shivani, A., 2014. An overview of history, pathogenesis and treatment of perforated peptic ulcer disease with evaluation of prognostic scoring in adults. *Ann. Med. Health Sci. Res.* 4, 22–29
43. Doll, R., Friedlander, P., Pygott, F., 1956. Dietetic treatment of peptic ulcer. *Lancet* 267, 5–9.
44. Ehrenfeld, I., Wallace, R.P., 1941. Iron as a therapeutic supplement in peptic ulcer therapy. *The Am. J. Surg.* 53, 470–474.

45. Richardson CT. Role of aggressive factors in the pathogenesis of peptic ulcer disease. *Scand J Gastroenterology*. 1990; 25(1): 37- 43.
46. Satoskar RS, Bhandarkar SD, Ainapure SS. Pharmacotherapy of Peptic Ulcer Disease. In: *Pharmacology and Pharmacotherapeutics*. Edn. 18th, Popular Prakashan, Mumbai. pp. 601 - 616.
47. Javed M, Amin K, Muhammad D, Husain A, Mahmood N. Prevalence of H.pylori. *Professional Med Sep* 2010;17(3):431-39.
48. Stenstrom B, Mendis A, Marshall B. *Helicobacter pylori*-the latest in diagnosis and treatment. *Aust Fam Physician* 2008;37(8):608-12.
49. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK): Overview of Peptic Ulcers
50. Ganong WF. *Review of Medical Physiology*. 21st ed. McGraw-Hill Publications; 2003. p.486-91.
51. Ramakrishnan K. Peptic ulcer disease. *Am Fam Physician* 2007;76(7):1005-12.
52. Holvoet J, Terriere L, Van Hee W, Verbist L, Fierens E, Hautekeete ML. Relation of upper gastrointestinal bleeding to non-steroidal anti-inflammatory drugs and aspirin: A case control-study. *Gut*. 1991;32(7):730-4.
53. Wallace JL, Mc Knight W, Reuter B, Vergnolle N. NSAID-induced gastric damage in rats: Requirement for inhibition of both cyclooxygenase 1 and 2. *Gastroenterology*. 2000;119(3):706-14.
54. Rodriguez LAG, Jick H. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. *Lancet*. 1994;343(8900):769-72.
55. Iwakiri R, Higuchi K, Kato M, Fujishiro M, Kinoshita Y, Watanabe T, et al. Randomised clinical trial: prevention of recurrence of peptic ulcers by rabeprazole in patients taking low-dose aspirin. *Aliment Pharmacol Ther*. 2014;40(7):780-95. doi: 10.1111/apt.12907.
56. Gunshefski L, Flancbaum L, Brodin RE, Frankel A. Changing patterns in perforated peptic ulcer disease. *Am Surg*. 1990;56(4):270-4.
57. Feliciano DV, Ojukwu JC, Rozycki GS, Ballard RB, Ingram WL, Salomone J, et al. The epidemic of cocaine-related juxtapyloric perforations: with a comment on the importance of testing for *Helicobacter pylori*. *Ann Surg*. 1999;229(6):801-4; discussion 804-6.
58. Ellis H. The diagnosis of benign and malignant pyloric obstruction. *Clin Oncol*. 1976;2(1):11-5.
59. Johnson CD, Ellis H. Gastric outlet obstruction now predicts malignancy. *Br J Surg*. 1990;77(9):1023-4.
60. Turck F. B. (1907). Further observations on the etiology and pathology of peptic ulcer. *British medical journal*, 1(2416), 922–926.
61. Choi, W., Choi, C.-H., Kim, Y.R., Kim, S.-J., Na, C.-S., Lee, H., 2016. HerDing: herb recommendation system to treat diseases using genes and chemicals. Database 2016.
62. Huang, T.-C., Tsai, S.-S., Liu, L.-F., Liu, Y.L., Liu, H.-J., Chuang, K.P., 2010. Effect of *Arctium lappa* L. in the dextran sulfate sodium colitis mouse model. *World J. Gastroenterol*. 16, 4193–4199.
63. Lin, L.-T., Hsu, W.-C., Lin, C.-C., 2014. Antiviral natural products and herbal medicines. *J. Traditional Complement. Med*. 4, 24–35.

64. Zhang, L., Zhuang, H., Zhang, Y., Wang, L., Zhang, Y., Geng, Y., Gou, Y., Pei, S., Wang, Y., 2018. Plants for health: An ethnobotanical 25-year repeat survey of traditional medicine sold in a major marketplace in North-west Yunnan, China. *J. Ethnopharmacol.* 224, 119–125.
65. Ghosh, V., Sugumar, S., Mukherjee, A., Chandrasekaran, N., 2016. Neem (*Azadirachta indica*) Oils. In: Preedy, V.R. (Ed.), *Essential Oils in Food Preservation, Flavor and Safety*. Academic Press, San Diego, pp. 593–599.
66. Kim, K.H., Lee, D., Lee, H.L., Kim, C.-E., Jung, K., Kang, K.S., 2018. Beneficial effects of Panax ginseng for the treatment and prevention of neurodegenerative diseases: past findings and future directions. *J. Ginseng Res.* 42, 239–247
67. Drobnic, K. et al. (2021). "Efficacy of Cabbage Juice in Peptic Ulcer Healing." *Journal of Gastroenterology and Nutrition*, 23(4), 450-457.
68. Rafatullah, S. et al. (2020). "Licorice: A Natural Treatment for Peptic Ulcers." *Phytotherapy Research*, 34(6), 897-903.
69. Pandey, R. et al. (2019). "Role of Aloe Vera in Ulcer Healing." *Journal of Herbal Medicine*, 10(3), 210-215.
70. Gupta, R. et al. (2020). "Turmeric and its Role in Peptic Ulcer Treatment." *Food and Nutrition Research*, 64, 1-12.
71. Dhar, A. et al. (2018). "Bananas in Gastrointestinal Health: A Review." *Indian Journal of Clinical Nutrition*, 16(2), 34-39.
72. Bandyopadhyay, U. et al. (2021). "Neem and its Role in Gastric Protection." *Journal of Ethnopharmacology*, 284, 114789.
73. Al-Yahya, M. et al. (2019). "Fenugreek Seeds in Peptic Ulcer Treatment." *Saudi Journal of Biological Sciences*, 26(4), 902-908.
74. M. Umamaheswari, K. Asokkumar, R. Rathidevi, A.T. Sivashanmugam, V. Subhadradevi and T.K. Ravi. Antiulcer and in vitro antioxidant activities of *Jasminum grandiflorum* L. *J Ethnopharmacol.* 110: 464–70 (2007)
75. M. Jainu and C.S.S. Devi. Antiulcerogenic and ulcer healing effects of *Solanum nigrum* (L.) on experimental ulcer models: possible mechanism for the inhibition of acid formation. *J Ethnopharmacol.* 104: 156–63 (2006).
76. M.S. Akthar and M. Munir. Evaluation of antiulcerogenic effect of *Solanum nigrum*, *Brassica oleracea* and *Ocimum basilicum* in rats. *J Ethnopharmacol.* 27: 163–72 (1989).
77. S. Godhwani, J.L. Godhwani and D.S. Vyas. *Ocimum sanctum*—an experimental study evaluating its anti-inflammatory, analgesic and antipyretic activity in animals. *J Ethnopharmacol.* 21: 153–63 (1987).
78. S. Singh, D.K. Majumdar and M.R. Yadav. Chemical and pharmacological studies on fixed oil of *Ocimum sanctum*. *Indian J Exp Biol.* 34: 1212–215 (1996)

79. K. Sairam, S. Priyambada, N.C. Aryya and R.K. Goel. Gastroduodenal ulcer protective activity of *Asparagus racemosus*: an experimental, biochemical and histological study. *J Ethnopharmacol.* 86: 1-10 (2003)
80. M.A. Jafri, Farah, K. Javed and S. Singh. Evaluation of the gastric antiulcerogenic effect of large cardamom (fruits of *Amomum subulatum* Roxb). *J Ethnopharmacol.* 75: 89–94 (2001).